The IHAT-GUT iron supplementation trial in rural Gambia: barriers, facilitators, and benefits

Isabelle Stelle; Lorraine K. McDonagh; Mohammad Ilias Hossain; Anastasia Z. Kalea; Dora I.A. Pereira

doi:10.1101/2020.09.30.20199992

ABSTRACT

Introduction In most sub-Saharan African countries iron deficiency anaemia remains highly prevalent in children and this has not changed in the last 25 years. Supplementation with iron hydroxide adipate tartrate (IHAT) was being investigated in anaemic children in a phase two clinical-trial (termed IHAT-GUT), conducted at the MRC Unit The Gambia at LSHTM (MRCG). This qualitative study aimed to explore the personal perceptions of the trial staff in relation to conducting a clinical trial in such settings in order to highlight the health system specific needs and strengths in the rural, resource-poor setting of the Upper River Region in The Gambia.

Methods Individual interviews (n=17) were conducted with local trial staff of the IHAT-GUT trial. Data were analysed using inductive thematic analysis.

Results Potential barriers and facilitators to conducting this clinical trial were identified at the patient, staff, and trial-management levels. Several challenges, such as the rural location and cultural context, were identified but noted as not being long-term inhibitors. Participants believed the facilitators and benefits outnumbered the barriers, and included the impact on education and healthcare, the ambitious and knowledgeable locally recruited staff and the local partnership.

Conclusion While facilitators and barriers were identified to conducting this clinical trial in a rural, resource poor setting, the overall impact was perceived as beneficial, and this study is a useful example of community involvement and partnership for further health improvement programs. To effectively implement a nutrition intervention, the local health systems and context must be carefully considered through qualitative research beforehand.

Competing Interest Statement

DIAP is one of the inventors of the IHAT iron supplementation technology, for which she could receive future awards to inventors through the MRC Awards to Inventor scheme. DIAP has served as a consultant for Vifor Pharma UK, Entia Ltd, Shield Therapeutics, Danone Nutritia, UN Food and Agriculture Organisation (FAO) and Nemysis Ltd. DIAP now works for Vifor Pharma UK, but all work pertaining to this publication was conducted whilst at the University of Cambridge and MRC Unit The Gambia at LSHTM. Notwithstanding, the authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Clinical Trial

NCT02941081

Funding Statement

IS was partly supported by a travel bursary from University College London. DIAP and the IHAT-GUT trial are supported by a Bill and Melinda Gates Foundation Grand Challenges New Interventions for Global Health award [OPP1140952]. The Nutrition Workshop was supported by the Cambridge-Africa Alborada Research Fund. The Nutrition Group of the MRC Unit The Gambia at LSHTM are supported by core funding MC-A760-5QX00 to the MRC Unit The Gambia/MRC International Nutrition Group by the UK MRC and the UK Department for the International Development (DFID) under the MRC/DFID Concordat agreement. The funders had no role in study design, field data collection and analysis, decision to publish, or preparation of this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was obtained from The Gambia Government/MRC Joint Ethics Committee (REF: L2018.25). Written and verbal informed consent for interviews and photographs was obtained from each participant. It was made clear that refusal to be involved would be confidential and would not affect their work; no participants refused to be interviewed.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes